Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310. doi: 10.1007/s00228-016-2110-5. Epub 2016 Aug 11.
Eur J Clin Pharmacol. 2016.
PMID: 27515978
Clinical Trial.
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Zhuang Y, de Vries DE, Xu Z, Marciniak SJ Jr, Chen D, Leon F, Davis HM, Zhou H.
Zhuang Y, et al. Among authors: marciniak sj jr.
J Clin Pharmacol. 2015 Dec;55(12):1386-94. doi: 10.1002/jcph.561. Epub 2015 Jul 29.
J Clin Pharmacol. 2015.
PMID: 26054042
Clinical Trial.
Item in Clipboard
Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.
Xu Z, Marciniak SJ Jr, Frederick B, Kim L, Zhuang Y, Davis HM, Zhou H.
Xu Z, et al. Among authors: marciniak sj jr.
Clin Ther. 2015 Feb 1;37(2):427-38. doi: 10.1016/j.clinthera.2014.09.012. Epub 2014 Oct 29.
Clin Ther. 2015.
PMID: 25438720
Clinical Trial.
Item in Clipboard
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.
Sofen H, et al. Among authors: marciniak sj jr.
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
J Allergy Clin Immunol. 2014.
PMID: 24679469
Free article.
Clinical Trial.
Item in Clipboard
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL.
Marciniak SJ Jr, et al.
Thromb Haemost. 2002 Jun;87(6):1020-5.
Thromb Haemost. 2002.
PMID: 12083481
Item in Clipboard
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ Jr, Jordan RE, Mascelli MA.
Marciniak SJ Jr, et al.
Thromb Haemost. 2001 Mar;85(3):539-43.
Thromb Haemost. 2001.
PMID: 11307828
Item in Clipboard
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE.
Mascelli MA, et al. Among authors: marciniak sj jr.
Am Heart J. 2000 Apr;139(4):696-703. doi: 10.1016/s0002-8703(00)90050-4.
Am Heart J. 2000.
PMID: 10740154
Item in Clipboard
Cite
Cite